US2019223433A1PendingUtilityA1

High density cell banking methods

Assignee: GENZYME CORPPriority: Mar 15, 2013Filed: Dec 13, 2018Published: Jul 25, 2019
Est. expiryMar 15, 2033(~6.6 yrs left)· nominal 20-yr term from priority
C12M 23/26C12M 29/10C12M 29/16C12M 41/46C12M 27/16C12M 45/22A01N 1/0284A01N 1/142A01N 1/162C12N 5/06C12M 3/06C12M 41/34C12M 41/26C12M 33/14
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The current disclosure provides a method for the creation of a high-density cryopreserved cell bank using perfusion culture techniques and non-centrifugal concentration of cells. Methods of production using this high-density cryopreserved cell bank are also provided.

Claims

exact text as granted — not AI-modified
1 . A non-centrifugal method for producing a high-density frozen mammalian cell bank, the method comprising:
 a) culturing mammalian cells in a perfusion bioreactor to a first cell density by continuously removing growth medium from a culture and replacing with fresh growth medium, wherein said bioreactor is coupled to a cell retention system comprising an alternating tangential flow filtration system including a filter;   b) non-centrifugally concentrating the cells cultured in the perfusion bioreactor coupled to the cell retention system, wherein the cells are concentrated to a second cell density greater than the first cell density by removing the growth medium from the culture using the filter and, thereby reducing the volume of the growth medium to produce a concentrated cell population of about 1×10 8  cells/mL;   c) cryopreserving the concentrated cell population to produce a high-density frozen mammalian cell bank, wherein the high-density frozen mammalian cell bank has a post-thaw viability of at least 90%, wherein the pH and DO of the culture are controlled by non-automated methods and, wherein the bioreactor is rocked at between 5 rpm and 22 rpm with a rock angle of between 5° and 10°.   
     
     
         2 . (canceled) 
     
     
         3 . The method of  claim 1 , wherein the filter has a surface area of at least 0.3 m 2 . 
     
     
         4 . The method of  claim 1 , wherein the filter has a surface area of about 0.5 to about 1.0 m 2 , about 0.7 to about 0.8 m 2 , about 2.0 to about 3.0 m 2 , or 4 to about 5 m 2 , optionally wherein the filter has a pore size of about 0.2 μm. 
     
     
         5 - 10 . (canceled) 
     
     
         11 . The method of  claim 1 , wherein the cryopreserving comprises adding DMSO to the concentrated cell population at a final concentration of about 5% to about 10%, vol/vol. 
     
     
         12 . The method of  claim 1 , wherein the cryopreserving comprises freezing at least a portion of the concentrated cell population in a container appropriate for storage under cryopreservation conditions. 
     
     
         13 . The method of  claim 12 , wherein the container is a vial, optionally wherein the vial has a volume of at least 2 mL. 
     
     
         14 . (canceled) 
     
     
         15 . The method of  claim 13 , wherein the container has a volume of about 5 mL. 
     
     
         16 . The method of  claim 1 , wherein the high-density frozen cell bank comprises about 4.5×10 8  viable cells. 
     
     
         17 . The method of  claim 12 , wherein the container is a cryobag, optionally wherein the cryobag has a volume of about 5 to about 150 mL. 
     
     
         18 . (canceled) 
     
     
         19 . The method of  claim 1 , wherein the high-density frozen cell bank has a cell density of about 1×10 8  cells/mL. 
     
     
         20 . The method of  claim 1 , wherein the perfusion rate in the perfusion bioreactor is at least about 0.2 nL/cell/day. 
     
     
         21 . The method of  claim 1 , wherein the perfusion bioreactor cell culture has a pH of about 7 and a dissolved oxygen concentration of at least about 40%. 
     
     
         22 . The method of  claim 1 , wherein the bioreactor is a flexible bag bioreactor. 
     
     
         23 . The method of  claim 22 , wherein the flexible bag bioreactor has a volume of 10 L. 
     
     
         24 . The method of  claim 22 , wherein the flexible bag bioreactor has a volume of at least 20 L, optionally wherein the flexible bag bioreactor further comprises at least one dip tube. 
     
     
         25 - 27 . (canceled) 
     
     
         28 . The method of  claim 1 , wherein the high-density frozen cell bank has a post-thaw viability of at least 95%. 
     
     
         29 . (canceled) 
     
     
         30 . The method of  claim 1 , wherein the mammalian cells are selected from the group consisting of: CHO, CHO-DBX11, CHO-DG44, CHO-S, CHO-K1, Vero, BHK, HeLa, COS, MDCK, HEK-293, NIH-3T3, W138, BT483, Hs578T, HTB2, BT20, T47D, NSO, CRL7030, HsS78Bst cells, PER.C6, SP2/0-Ag14, and hybridoma cells, optionally wherein the cells are transfected cells. 
     
     
         31 . (canceled) 
     
     
         32 . A non-centrifugal method for producing a high-density frozen mammalian cell bank, the method comprising:
 a) culturing mammalian cells in a perfusion bioreactor to a cell density less than 1×10 8  cells/mL by continuously removing growth medium from a culture and replacing with fresh growth medium, wherein the perfusion bioreactor is coupled to an alternating tangential flow filtration system having a filter, wherein the bioreactor comprises a flexible bag bioreactor, and wherein the filter has a filter surface area of at least 0.3 m 2  and a filter with a MWCO size of at least 50 kDa;   b) non-centrifugally concentrating the cells cultured in the perfusion bioreactor coupled to the cell retention system, wherein the cells are concentrated by removing growth medium from the culture and, reducing the volume of the growth medium using the alternating tangential flow filtration system to produce a concentrated cell population having a density of about 1×10 8  cells/mL;   c) cryopreserving the concentrated cell population to produce a high-density frozen mammalian cell bank, wherein the cryopreserving comprises adding DMSO to the concentrated cell population to a final concentration of about 5% to about 10%, vol/vol;   and wherein the high-density frozen mammalian cell bank has a cell density of about 10 8  cells/ml, and wherein the high-density frozen mammalian cell bank has a post-thaw viability of at least 90%, wherein the pH and DO of the culture are controlled by non-automated methods and, wherein the bioreactor is rocked at between 5 rpm and 22 rpm with a rock angle of between 5° and 10°.   
     
     
         33 - 35 . (canceled) 
     
     
         36 . The method of  claim 1 , wherein the bioreactor is rocked at 15 rpm with a rock angle of 8°. 
     
     
         37 . The method of  claim 32 , wherein the bioreactor is rocked at 15 rpm with a rock angle of 8°.

Join the waitlist — get patent alerts

Track US2019223433A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.